



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**Oversight Committee Meeting Minutes**  
**August 17, 2022**

NOTE: Unless the information is confidential, the reports, presentations, and grant award information referenced in the minutes are available at <http://ocmeetings.cprit.texas.gov> in the "Oversight Committee Board Packet" section for the corresponding meeting date.

**Call to Order – Agenda Item 1**

Presiding Officer Dr. Mahendra Patel announced a quorum present and called the meeting to order at 9:00 a.m.

**Roll Call/Excused Absences – Agenda Item 2**

Committee Members Present

Mahendra Patel, M.D., P.A.

David Cummings, M.D. (attended by videoconference pursuant to by Tex. Gov't Code § 551.127)

Donald (Dee) Margo

Ambrosio Hernandez, M.D.

Will Montgomery (attended by videoconference pursuant to by Tex. Gov't Code § 551.127)

Cindy Barberio Payne

Bill Rice, M.D.

Craig Rosenfeld, M.D.

Presiding Officer Dr. Patel noted for the record that Oversight Committee members Mr. Montgomery and Dr. Cummings are attending the meeting via videoconference, as permitted by the Texas Open Meetings Act.

**Adoption of Minutes from the May 18, 2022, Meeting – Agenda Item 3 – Tab 1**

**MOTION:**

On a motion by Mr. Margo and seconded by Dr. Rice, the Oversight Committee unanimously voted to approve the minutes of the May 18, 2022, Oversight Committee meeting as presented.

**Public Comment – Agenda Item 4**

Presiding Officer Dr. Patel noted for the record that no member of the public requested to provide comments.

## **Grantee Presentation – Agenda Item 5, Tab 2**

Presiding Officer Dr. Patel recognized Dr. Le Beau to introduce Dr. Robert Alan Hromas, Dean of the Long School of Medicine at The University of Texas Health Science Center San Antonio. Dr. Hromas provided an overview of his CPRIT funded research and the overall impact of CPRIT funding at UTHealth San Antonio.

Following his presentation, Oversight Committee members discussed some of the scientific points of Dr. Hromas' report with him, including pancreatic cancer, prostate cancer, and FDA regulatory approval issues.

An Oversight Committee member talked with Dr. Hromas about the South Texas clinical trial catchment area and available training opportunities. They also discussed the timeline to clinical trials for Dr. Hromas' CPRIT-funded work with T-Cell lymphoma and T-Cell Lymphoma Consortium.

Dr. Patel and Oversight Committee members thanked Dr. Hromas for his presentation.

## **Chief Executive Officer Report – Agenda Item 6, Tab 3**

Presiding Officer Dr. Patel recognized Chief Executive Officer Wayne Roberts to present his report.

Mr. Roberts informed members regarding the amount of funds available for the remainder of the fiscal year and indicated that if the board approved the 21 awards, a \$3.5 million balance would exist for the remainder of the fiscal year.

Mr. Roberts introduced new staff to the Oversight Committee. He also reminded members that CPRIT will hold a special Oversight Committee meeting in September and one in January 2023.

## **Chief Compliance Officer Report and Compliance Certification for the Proposed Grant Awards – Agenda Item 7, Tab 4**

Presiding Officer Dr. Patel recognized Chief Compliance Officer Vince Burgess to present the Compliance Report and Compliance Certification of Grant Award Process.

Following Mr. Burgess' presentation of the compliance activities, an Oversight Committee member commented that the approximately \$170,000 in unallowable match expenses found by compliance staff is a relatively small amount. Mr. Burgess agreed that the extensive training CPRIT provides to the grantees likely helped keep the unallowable match expenses amount low.

An Oversight Committee member asked if CPRIT had made progress regarding allowing other grantee institutions that the statute does not define as Texas institutions of higher education to utilize their Federal Indirect Cost Rate to meet the CPRIT matching requirement. Mr. Roberts responded that a bill filed last legislative session addressed the issue but did not make it out of committee.

Following his report, Mr. Burgess presented the Compliance Certification for the proposed academic research grant awards, confirming that the proposed awards and review process complied with all applicable state and agency requirements.

**Chief Scientific Officer Report and Grant Award Recommendations – Agenda Item 8, Tab 5**

Presiding Officer Dr. Patel recognized Chief Scientific Officer Dr. Michelle Le Beau to present her program report and the academic research award recommendations.

Dr. Le Beau directed Oversight Committee members to Table 1 on page 6 of the Proposed Grant Awards Book which displayed the Scientific Review Council (SRC) and Program Integration Committee (PIC) recommendations for the FY2022 Recruitment Cycles 22.10 which included 3 applications totaling \$10,000,000.

***Cycle 22.10 Recommended Recruitment Awards***

<b>Rank</b>	<b>ID</b>	<b>RFA</b>	<b>Candidate</b>	<b>Organization</b>	<b>Budget</b>	<b>Overall Scores</b>
1	RR220094	RFTFM	Steven Boeynaems, Ph.D.	Baylor College of Medicine	\$2,000,000	1.0
2	RR220101	RFTFM	Siqi Liu, Ph.D.	University of Texas Southwestern Medical Center	\$2,000,000	1.0
3	RR220067	REI	Zhiguo Zhang, Ph.D.	The University of Texas M. D. Anderson Cancer Center	\$6,000,000	2.0
<b>Total</b>					\$10,000,000	

REI = Recruitment of Established Investigator  
RFTFM = Recruitment of First-Time, Tenure Track Faculty Members

**Approval Process – Academic Research Awards**

Presiding Officer Dr. Patel noted for the record that no Oversight Committee member had reported a conflict with any award recommendations presented today.

**MOTION:**

On a motion made by Mr. Margo and seconded by Dr. Rice the Oversight Committee members voted unanimously to approve the PIC’s recommendations for the Recruitment of First-Time, Tenure-Track Faculty Members and Recruitment of Established Investigators.

**MOTION:**

On a motion made by Mr. Margo and seconded by Dr. Rice, the Oversight Committee members voted to approve the delegation of contract negotiation authority to CPRIT’s CEO and staff and authorized the CEO to sign the contracts on behalf of CPRIT.

**Chief Prevention Officer Report and Grant Award Recommendations – Agenda Item 9, Tab 6**

Presiding Officer Patel recognized Chief Prevention Officer Ramona Magid to present the prevention awards and to update the Oversight Committee on the prevention program. Ms. Magid first provided an update on the status of applications for the first review cycle of FY2023.

Following her update, Ms. Magid introduced the nine prevention program projects, totaling \$14,443,836, recommended for awards in the second cycle of FY 2022 by the Prevention Review Council (PRC) and PIC. She explained that applicants submitted the recommended applications in response to two grant mechanisms: *Evidence-Based Cancer Prevention Services and Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations*. Ms. Magid reported that all applications address one or more of the Prevention Program priorities.

**Cycle 22.2 Recommended Prevention Program Awards**

ID	RFA	Project	PD	Organization	Score	Rank Order	Budget
PP220036	EBP	Increasing the use of HPV vaccination services among medically underserved young adults	Roncancio, Angelica M	University of Houston	1.6	1	\$991,308
PP220034	EPS	Screening to Optimize Prevention of CRC in East Texas (STOP CRC ET)	McGaha, Paul	The University of Texas Health Center at Tyler	1.8	2	\$2,482,127
PP220038	EPS	Advancing Implementation of Evidence-Based Strategies for Tobacco Prevention and HPV Vaccination in Pediatric Safety Net Settings	Montealegre, Jane R	Baylor College of Medicine	2.3	3	\$2,499,180
PP220045	EBP	Inpatient Screening and Treatment for Unhealthy Alcohol Use and Tobacco Use as a means of cancer prevention	Ramesh, Jananie	The University of Texas at Austin	2.6	4	\$999,957
PP220037	EPS	Project ACCESS: Increasing Access to Cervical Cancer Screening & Treatment Services in Texas	Schmeler, Kathleen M	The University of Texas M. D. Anderson Cancer Center	2.9	5	\$2,498,445
PP220024	EBP	Promoting Prevention in Survivorship Care in Rural Texas	Kvale, Elizabeth	The University of Texas at Austin	3.3	6	\$975,851
PP220041	EBP	Fecal Immunochemical Testing for Screening and Treatment of Occult Neoplasia (FIT-STOP)	Layeequr Rahman, Rakhshanda	Texas Tech University Health Sciences Center	4.0	7	\$999,999

ID	RFA	Project	PD	Organization	Score	Rank Order	Budget
PP220051	EPS	Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations- Program title: GetFIT	Mika, Virginia	University Health System	4.5	8	\$1,999,849
PP220035	EBP	DEFEAT breast cancer: Delivering Education, Focused navigation, and Equitable Access throughout East Texas.	McGaha, Paul	The University of Texas Health Center at Tyler	5.0	9	\$997,120
<b>TOTAL</b>							\$14,443,836

EBP: Evidence-Based Cancer Prevention Services

EPS: Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations

An Oversight Committee member asked Ms. Magid to provide more detail on the project scoring 5.0. She responded that the PRC conducts a programmatic portfolio review, taking into consideration geographic distribution, population served, type of program and cancer type, to balance the portfolio. She explained that the PRC felt that the need addressed by the project justified the award and that the project weaknesses noted during review were ones that CPRIT and the grantee could address during contract negotiation. The PRC considered the success of projects led by the Program Director in making the assessment.

#### Approval Process – Prevention Grant Awards

Presiding Officer Dr. Patel noted for the record that no Oversight Committee member had reported a conflict with any award recommendations presented today.

#### **MOTION:**

On a motion made by Mr. Margo and seconded by Dr. Rice the Oversight Committee members voted unanimously to approve the PIC's award recommendations for the Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations and Evidence-Based Cancer Prevention Services grant mechanisms.

#### **MOTION:**

On a motion made by Dr. Margo and seconded by Dr. Rice, the Oversight Committee members voted to approve the delegation of contract negotiation authority to CPRIT's CEO and staff and authorized the CEO to sign the contracts on behalf of CPRIT.

#### **Chief Product Development Officer Report – Agenda Item 10, Tab 7**

Presiding Officer Dr. Patel recognized Interim Chief Product Development Officer Dr. Ken Smith to present the Product Development Research update and the recommended product development awards.

Dr. Ken Smith updated the Oversight Committee on the product development program including the anticipated release of FY 2023 RFAs.

Following his report, Dr. Smith presented the nine award recommendations.

**Cycle 22.2 Recommended Product Development Research Program Awards**

Rank	ID	RFA	Company	Project	Score*	Budget
1	DP220039	TXCO	PLUS Therapeutics Inc.	Single-Dose 186RNL for Leptomeningeal Metastases: Multicenter Phase 1/2a Study to Determine MTD/MFD, Safety and Efficacy, Leading to Pivotal Registrational Trial	2.2	\$17,613,605
2	DP220028	SEED	Stellanova Therapeutics Inc.	Development of DKK3-Targeted Therapeutic Antibodies for Cancer	2.3	\$3,000,000
3	DP220038	SEED	Asyilia Therapeutics	Humanization, Validation, and Clinical Translation of Cell Surface Heat Shock Protein 70-Targeted Antibody-Drug Conjugates for T-Cell Non-Hodgkin Lymphomas	2.3	\$3,000,000
4	DP220055	TXCO	Atom Mines	Commercial-Scale Enrichment of Stable Ytterbium-176 for Production of No-Carrier-Added Lutetium-177 for Use in Prostate Cancer Therapy	2.0	\$2,500,000
5	DP220053	TXCO	Rapamycin Holdings Inc.	Development of eRapa for the Treatment of Familial Adenomatous Polyposis, a Rare Genetic Disease Associated with a High Risk of Colorectal Cancer	2.7	\$16,999,999
6	DP220043	SEED	Xerient Pharma Inc.	Oral Amifostine as an Upper GI Tract Radioprotectant for Effective Radiotherapy Treatment of Pancreatic Cancer	2.2	\$2,934,737
7	DP220063	SEED	InformAI Inc.	RadOnc-AI: An Artificial Intelligence Guided Dose-Prediction Platform for Radiation Oncology	2.2	\$1,552,000
8	DP220066	RELCO	PanTher Therapeutics Inc.	Enhancing Cancer Treatment through Direct, Localized, and Sustained Delivery of Therapeutic Agents: Clinical Evaluation in Locally Advanced Pancreatic Cancer	3.6	\$14,268,315
9	DP220054	SEED	Nucore Medical	Clinical Validation of the MiTR Core (Minimally Invasive Targeted Resection) Technology for Early Lung Cancer Intervention	3.4	\$2,999,999
<b>TOTAL</b>						<b>\$ 64,868,655</b>

An Oversight Committee member asked how CPRIT determines whether a company has relocated to Texas. Dr. Smith explained that CPRIT has specific criteria in its administrative rules that the company must fulfill.

Approval Process – Product Development Research Awards

Presiding Officer Dr. Patel noted for the record that Oversight Committee member Dr. Cummings reported a conflict of interest with one application, submitted by Rapamycin Holdings, recommended for an award. No other members reported any conflicts.

Presiding Officer Dr. Patel requested a vote on Rapamycin Holdings.

**MOTION:**

On a motion made by Mr. Margo and seconded by Dr. Rice the Oversight Committee members voted unanimously by members present and able to vote to approve the PIC's recommendation for the product development research award to Rapamycin Holdings as presented by Dr. Smith.

Presiding Officer Dr. Patel noted for the record that Dr. Cummings did not vote on the award recommendation.

**MOTION:**

On a motion made by Mr. Margo and seconded by Dr. Rice the Oversight Committee members voted unanimously to approve the PIC's recommendations for the product development research awards to the remaining eight companies as presented by Dr. Smith.

**MOTION:**

On a motion made by Mr. Montgomery and seconded by Dr. Rice, the Oversight Committee members voted to approve the delegation of contract negotiation authority to CPRIT's CEO and staff and authorized the CEO to sign the contracts on behalf of CPRIT.

**MOTION:**

On a motion made by Mr. Margo and seconded by Dr. Rice, the Oversight Committee unanimously voted to authorize CPRIT to disburse grant funds via advance upon execution of the award contracts and the successful completion of tranches to the nine companies approved by the Oversight Committee.

**Internal Auditor Report – Agenda Item 11, Tab 8**

Presiding Chair Patel recognized Dan Graves of Weaver and Tidwell, LLP, CPRIT's contracted internal auditor, to give the Internal Auditor's Report. Mr. Graves summarized the schedule of audits and highlighted the two in progress, vendor contract compliance and a compliance check on procurement. He presented the proposed internal audit plan for FY 2023. If approved, CPRIT will include the audit plan in the 2023 Annual Internal Audit Report that is due to the State Auditor's Office, Legislative Budget Board and Governor's Office in November.

An Oversight Committee asked Mr. Graves about the status of the records management audit that Weaver proposed to cancel. Mr. Graves explained that due to several reasons, including that IT staff would need to be heavily involved in the records management work while they would be undertaking substantial work on other follow up procedures, CPRIT and Weaver determined that cancelling the audit at this time was appropriate. Mr. Graves noted that he had previously informed the Oversight Committee of the decision at the May meeting.

**MOTION:**

On a motion by Mr. Margo and seconded by Dr. Rice, the Oversight Committee unanimously voted to approve the fiscal year 2023 Audit Plan.

**Scientific Research and Prevention Program Committee Appointments – Agenda Item 12, Tab 9**

Presiding Chair Patel recognized Mr. Roberts to present his 27 appointments to the peer review panels.

**MOTION:**

On a motion by Mr. Margo and seconded by Dr. Rice, the Oversight Committee unanimously voted to approve the CEO's 27 appointments to the Scientific Research and Prevention Program Committee.

**Advisory Committees – Item 13, Tab 10**

Clinical Trial Advisory Committee presentation

Presiding Officer Dr. Patel called on Dr. Le Beau to introduce Dr. Gail Eckhardt, Chair of the Clinical Trials Advisory Committee (CTAC) to provide the CTAC Annual Report.

Dr. Le Beau introduced Dr. Eckhardt

Dr. Eckhardt presented the CTAC annual report.

Following the presentation, an Oversight Committee member encouraged CPRIT to be more aggressive in moving clinical trial resources to rural areas.

In response to a question by an Oversight Committee member inquiring of the ethnicity of patients enrolled in clinical trials, Dr. Le Beau explained that of the 40,165 individuals in CPRIT-supported clinical trials, 10,931 are Hispanic, about 27%.

Oversight Committee members discussed the appropriate target for enrollment of cancer patients in rural areas in clinical trials. Dr. Eckhardt explained that NCI designated centers provide some data, but that data were lacking for areas of West Texas. More data are necessary to set the goal. Another Oversight Committee member asked Ms. Magid about whether data from cancers detected in prevention program screenings may help provide the data needed. Ms. Magid explained that CPRIT does not collect cancer detection information by specific county because of HIPAA regulations.

An Oversight Committee asked Dr. Eckhardt about clinical trial lead centers and regional centers and the incentives for lead centers to support regional centers. Dr. Eckhardt responded that NCI mandates that NCI-designated cancer center provide trials equally throughout the catchment area but fulfilling the requirement can be difficult.



Presiding Officer Dr. Patel and the Oversight Committee members thanked Dr. Eckhardt for the presentation.

#### **FY 2023 Honoraria Policy – Item 14, Tab 11**

Presiding Chair Patel recognized Mr. Roberts to present the FY 2023 Honoraria Policy.

Mr. Roberts summarized the changes to the FY 2023 honoraria policy, which impacted the product development research program. The changes were necessary to accommodate the changes in the product development research program review process.

#### **MOTION:**

On a motion made by Dr. Rosenfeld and seconded by Mr. Margo, the Oversight Committee unanimously voted to approve the FY 2023 honoraria policy.

#### **Health & Safety Code § 102.1062 Waivers – Item 15, Tab 12**

Presiding Chair Patel recognized Mr. Roberts. He presented the FY 2023 conflict of interest waivers provided behind tab 12 in the meeting book.

#### **MOTION:**

On a motion made by Dr. Rosenfeld and seconded by Mr. Margo, the Oversight Committee unanimously voted to approve the FY 2023 § 102.1062 Waivers.

#### **Amendments to 25 T.A.C. Chapters 703 – Item 16, Tab 13**

Presiding Chair Patel recognized Cameron Eckel. Ms. Eckel presented five proposed rule changes to Chapter 703.

In response to a question by an Oversight Committee member to restate the grantee relocation expenses, Ms. Eckel answered that TAC § 703.11 provides examples and categories for eligible expenses and CPRIT has added relocation expenses.

#### **MOTION:**

On a motion made by Mr. Montgomery and seconded by Mr. Margo, the Oversight Committee unanimously voted to publish the proposed changes to the Texas Administrative Code Chapter 703 in the *Texas Register*.

#### **Chief Operating Officer Report – Agenda Item 17, Tab 14**

Presiding Chair Patel recognized Chief Operating Officer Heidi McConnell. Ms. McConnell presented her report, including an update on FY 2023 contracts for financial audit services and outside counsel services that are under the \$100,000 threshold. She also informed members that the agency is working on assigning each member a CPRIT-specific email address, which will also require members to undergo training regarding information security.

In response to a question by an Oversight Committee member inquiring why CPRIT-domain email addresses are necessary for members, Ms. McConnell responded that CPRIT initiated this project pursuant to requests from several OC members.

**Contract Approvals – Agenda Item 18, Tab 15**

Ms. McConnell reviewed the proposed contracts with The Perryman Group, Weaver and Tidwell, and Moody Gardens Hotel, Spa and Convention Center.

Ms. McConnell clarified the contract with Moody Gardens Hotel in Galveston includes estimated costs for food and beverage catering (\$200,000) and for audiovisual support services (\$52,000). However, the catering costs may end up being higher if conference registrations are greater than the estimated 750 attendees used in the bidding process. She explained that CPRIT selected Moody Gardens Hotel as the conference venue because of the available dates, various concessions and discounts, and the fact that the conference facilities and hotel are co-located in one venue.

There were no questions for Ms. McConnell.

**MOTION:**

On a motion made by Dr. Rosenfeld and seconded by Dr. Rice, the Oversight Committee unanimously voted to approve the contracts with The Perryman Group, Weaver and Tidwell, and Moody Gardens Hotel.

**Intellectual Property Project Update – Agenda Item 19, Tab 16**

Presiding Chair Dr. Patel recognized Chief Strategic Initiatives and Intellectual Property Officer Tracey Davies. Ms. Davies updated the Oversight Committee on CPRIT's ongoing project to streamline and standardize grantees' reporting of CPRIT-funded intellectual property.

In response to a question by an Oversight Committee member inquiring if CPRIT grantees routinely provide disclosure notices, Ms. Davies confirmed that grantees regularly submit disclosures pursuant to the grant contract requirements and that CPRIT considers the information confidential.

Ms. Davies responded to another Oversight Committee member's question, explaining that grantees have reported 557 published patent applications and 110 patents issued.

Oversight Committee members discussed with Ms. Davies the future opportunity to share information about invention disclosures.

**Communication Report – Agenda Item 20, Tab 17**

Presiding Chair Dr. Patel recognized Communications Director Mark Loeffler to present his report. Mr. Loeffler updated the committee members on communications activities.

**Future Meeting Dates and Agenda Items – Agenda Item 24, Tab 18**

Presiding Chair Dr. Patel announced that the Oversight Committee would not take up standing agenda items 21, 22 and 23.

He referred to the proposed dates for regular quarterly meetings and subcommittee meetings for FY 2023 in the meeting book behind tab 18.

**MOTION:**

On a motion made by Mr. Margo and seconded by Dr. Rice, the Oversight Committee unanimously voted to approve the proposed meeting dates for the regular meetings of the Oversight Committee and subcommittees for FY 2023.


He reminded members that CPRIT will hold a special meeting on September 14.


**Adjournment – Agenda Item 25**

**MOTION:**

There being no further business, the Oversight Committee unanimously voted to approve Presiding Chair Patel’s motion to adjourn, which Dr. Rosenfeld seconded.

Meeting adjourned at 12:18 p.m.

  
\_\_\_\_\_  
Signature

  
\_\_\_\_\_  
Date

*Cynthia Barberis Payne 11/16/22*

# LUDWIG CANCER RESEARCH

San Diego

[ludwigcancerresearch.org](http://ludwigcancerresearch.org)

*Cindy Barbario Payne*  
8/17/2022

Rank	App. ID	Mechanism	Candidate	Organization	Budget	Overall Scores
1	RR220084	RFTFM	Linde Miles	The University of Texas Southwestern Medical Center	\$2,000,000	1.0
2	RR220087	RRS	Hans Renata	Rice University	\$4,000,000	1.0
3	RR220068	RFTFM	Elizabeth Wasmuth	The University of Texas Health Science Center at San Antonio	\$2,000,000	1.0
4	RR220069	RFTFM	William Hudson	Baylor College of Medicine	\$2,000,000	1.0
5	RR220075	RFTFM	Nicholas Riley	The University of Texas at Austin	\$2,000,000	1.0
6	RR220033	REI	Pavan Reddy	Baylor College of Medicine	\$6,000,000	1.0
7	RR220062	RFTFM	Aria Vaishnavi	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	1.0
8	RR220065	RFTFM	Mingjie Dai	Rice University	\$2,000,000	1.4
9	RR220072	RRS	Christine Lovly	The University of Texas M. D. Anderson Cancer Center	\$4,000,000	1.4
10	RR220063	RRS	Ku-Lung Hsu	The University of Texas at Austin	\$4,000,000	1.7
11	RR220051	REI	Michael Taylor	Baylor College of Medicine	\$6,000,000	1.8
12	RR220081	RFTFM	Jonathan Clinger	Baylor University	\$1,998,029	2.0
13	RR220086	RFTFM	Jason Schenkel	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	2.0
14	RR220088	RRS	Abdel Kareem Azab	The University of Texas Southwestern Medical Center	\$2,000,000	2.0
15	RR220067	REI	Zhiguo Zhang	The University of Texas M. D. Anderson Cancer Center	\$6,000,000	2.0
16	RR220070	RRS	Marios Giannakis	The University of Texas Southwestern Medical Center	\$4,000,000	2.0
17	RR220055	RFTFM	Samantha Yruegas	Rice University	\$2,000,000	2.0
18	RR220066	RFTFM	Deepshika Ramanan	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	2.2
19	RR220035	RFTFM	Qian Zhu	Baylor College of Medicine	\$2,000,000	2.5

REI = Recruitment of Established Investigator

RRS = Recruitment of Rising Stars

RFTFM = Recruitment of First-Time, Tenure Track Faculty Members

# LUDWIG CANCER RESEARCH

San Diego

  
Cindy Barberio Payne  
8/17/2022

[ludwigcancerresearch.org](http://ludwigcancerresearch.org)

Rank	App. ID	Mechanism	Candidate	Organization	Budget	Overall Scores
1	RR220094	RFTFM	Steven Boeynaems, Ph.D.	Baylor College of Medicine	\$2,000,000	1.0
2	RR220101	RFTFM	Siqi Liu, Ph.D.	The University of Texas Southwestern Medical Center	\$2,000,000	1.0

RFTFM = Recruitment of First-Time, Tenure Track Faculty Members